Kids get extra year of promising Muscle-Weakness drug in safety Follow-Up
NCT ID NCT06435312
Summary
This study is giving children with a rare autoimmune muscle-weakening disease an extra year of an experimental drug to check its long-term safety. It's open to kids aged 2 and up who finished a previous trial and whose doctors think they could benefit from continuing treatment. The main goal is to see if the daily injection is well-tolerated over a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mg0015 20104
Seoul, South Korea
-
Mg0015 20220
Seoul, South Korea
-
Mg0015 40144
Milan, Italy
-
Mg0015 40218
Warsaw, Poland
-
Mg0015 40735
Glasgow, United Kingdom
-
Mg0015 40736
London, United Kingdom
-
Mg0015 40774
Katowice, Poland
Conditions
Explore the condition pages connected to this study.